Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has today filed an appeal for rejection of UK Drug Tariff reimbursement
With support from external advisors, Biotec has evaluated the decision by the Drug Tariff authority under NHS to reject the application for remuneration of Woulgan for wound treatment in UK, and concluded that there are good reasons for appeal within the framework of NHS’ own guidelines.
-“We have consulted with specialist UK healthcare lawyers regarding the application. Having considered our application and correspondence with the NHS, they have advised us that there are grounds for an appeal which is in line with our own opinion of the matter”, says Svein Lien, CEO of Biotec Pharmacon.
The appeal will be reviewed by a separate NHS panel according to predefined criteria. The process does not allow Biotec to submit any further documentation while the appeal is being processed. According to the NHS guidance to manufacturers, Biotec should expect a decision by the appeal board within 3 months from submission.
If the appeal is positive, then the Drug Tariff will review the application again, taking into account any guidance from the appeal panel.